Abstract
Fos expression in the globus pallidus (GP) of rats was elicited by the D2 agonist quinpirole both ipsilateral and contralateral to a unilateral nigrostriatal 6-hydroxydopamine (6-OHDA) injection; however, the 6-OHDA-treated hemisphere was more sensitive to this effect. The quinpirole-induced GP Fos expression was antagonized in both hemispheres by the D2 antagonist eticlopride, but not by the D1 antagonist SCH 23390. In neurologically intact rats, the D1 agonist SKF 38393, which alone did not elicit pallidal Fos expression, augmented the quinpirole-induced Fos response. Thus, D1 agonists can synergize with D2 agonists in inducing GP c-fos; but the D2-stimulated induction does not depend on concurrent D1 agonism.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
-
Animals
-
Benzazepines / pharmacology
-
Corpus Striatum / drug effects
-
Corpus Striatum / pathology
-
Corpus Striatum / physiology*
-
Dopamine Agents / pharmacology*
-
Dopamine D2 Receptor Antagonists
-
Ergolines / pharmacology*
-
Functional Laterality
-
Gene Expression / drug effects*
-
Genes, fos*
-
Globus Pallidus / drug effects
-
Globus Pallidus / metabolism*
-
Male
-
Oxidopamine
-
Proto-Oncogene Proteins c-fos / analysis
-
Proto-Oncogene Proteins c-fos / biosynthesis*
-
Quinpirole
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Dopamine D1 / antagonists & inhibitors
-
Receptors, Dopamine D1 / physiology
-
Receptors, Dopamine D2 / drug effects
-
Receptors, Dopamine D2 / physiology*
-
Salicylamides / pharmacology
-
Substantia Nigra / drug effects
-
Substantia Nigra / pathology
-
Substantia Nigra / physiology*
Substances
-
Benzazepines
-
Dopamine Agents
-
Dopamine D2 Receptor Antagonists
-
Ergolines
-
Proto-Oncogene Proteins c-fos
-
Receptors, Dopamine D1
-
Receptors, Dopamine D2
-
Salicylamides
-
Quinpirole
-
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
-
Oxidopamine
-
eticlopride